BrainStorm gets FDA fast-track status for ALS stem cell therapy – Raw Story
Raw Story |
BrainStorm gets FDA fast-track status for ALS stem cell therapy
Raw Story Israel's BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a “fast-track” product for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm's treatment, called NurOwn, is … Brainstorm's Stem Cell Based Drug NurOwn Gets FDA Fast Track Approval |
